Li Haiping, Qiang Luo, Zhang Chunyang, Wang Chaohui, Mu Zhenxing, Jiang Ligang
Department of Neurology, Affiliated Hospital of Beihua University, Jilin, Jilin Province, China.
Neural Regen Res. 2014 Sep 1;9(17):1635-42. doi: 10.4103/1673-5374.141792.
Acute ischemic stroke has become a major disease burden with high mortality and morbidity rates. There is a lack of evidence-based medicine confirming the efficacy of common treatments. Panax notoginseng saponins, the main active ingredient of radix notoginseng, have a neuroprotective role in ischemic brain injury, and have been popularized as a maintenance treatment for acute cerebral infarction and its sequelae. We conducted literature searches on the Web of Science, ClinicalTrials.gov, Cochrane Collaboration, CNKI, Wanfang and the China Scientific & Technological Achievements Database and analyzed the experimental and clinical outcomes of studies investigating the use of radix notoginseng in the treatment of ischemic brain injury to improve the understanding of relevant research trends and existing problems. We found that over the past 10 years, China has maintained its interest in Panax notoginseng research, while such studies are scarce on the Web of Science. However, Chinese researchers often focus on the neuroprotective role of radix notoginseng in ischemic brain injury, but there are no large-scale clinical data to confirm its efficacy and safety. There remains a need for more rigorous large-sample randomized controlled clinical trials with long-term follow-up, to determine whether radix notoginseng lowers stroke recurrence and improves patient's quality of life.
急性缺血性中风已成为一种主要的疾病负担，死亡率和发病率都很高。缺乏循证医学来证实常用治疗方法的疗效。三七皂苷是三七的主要活性成分，在缺血性脑损伤中具有神经保护作用，并已作为急性脑梗死及其后遗症的维持治疗方法得到推广。我们在科学网、ClinicalTrials.gov、Cochrane协作网、中国知网、万方和中国科技成果数据库上进行了文献检索，并分析了研究三七治疗缺血性脑损伤的实验和临床结果，以增进对相关研究趋势和现存问题的了解。我们发现，在过去10年里，中国一直对三七研究保持关注，而在科学网上此类研究却很稀少。然而，中国研究人员常常关注三七在缺血性脑损伤中的神经保护作用，但尚无大规模临床数据来证实其疗效和安全性。仍需要进行更严格的、有长期随访的大样本随机对照临床试验，以确定三七是否能降低中风复发率并改善患者生活质量。
